What funding framework is industry seeking from the Union Budget 2026 for pharma and MedTech?

Industry leaders are calling for a structured funding framework to deepen innovation and R&D in the pharmaceutical and MedTech sectors.

How can the Union Budget 2026 support MedTech manufacturing in India?

The budget can support MedTech by reducing cost disabilities, nurturing local innovation, enabling faster market access, and providing focused public investment in R&D.

What is the industry's vision for Viksit Bharat and healthcare?

The vision includes advancing complex therapies, improving patient access, developing a prevention-first healthcare system, and leveraging AI for innovation.

Home / Business and Economy / Pharma & MedTech Seek Budget Boost for Innovation

Pharma & MedTech Seek Budget Boost for Innovation

22 Jan

•

Summary

Industry leaders want a structured funding framework for pharma and MedTech.
Companies aim for value-driven growth and complex therapy development.
Calls for tax rationalisation and public investment in R&D infrastructure.

Ahead of the Union Budget 2026, leaders from India's pharmaceutical and MedTech industries are advocating for a structured funding framework to accelerate innovation and research and development. This initiative is seen as crucial for advancing complex therapies and achieving the national vision of Viksit Bharat.

Industry stakeholders highlight a strategic shift towards value-driven growth. They call for closer alignment between science, policy, and industry to foster innovation across the entire value chain, enabling the translation of advanced research into high-value treatments.

Specific proposals include a Rs 1,000-crore MedTech R&D and clinical-validation fund. Concerns were also raised about inverted duty structures impacting MedTech manufacturers, urging for customs duty rationalisation and a simplified governance framework to boost cost competitiveness.